These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1358500)

  • 21. Treatment of Parkinson's disease.
    Lieberman A
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):339-43. PubMed ID: 8507903
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early idiopathic parkinsonism: initiation and optimization of treatment.
    Calne DB
    Clin Neuropharmacol; 1994; 17 Suppl 2():S14-8. PubMed ID: 9358191
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ; Kaplitt MG; Stern MB; Eidelberg D
    Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of deprenyl and levodopa on the progression of Parkinson's disease.
    Olanow CW; Hauser RA; Gauger L; Malapira T; Koller W; Hubble J; Bushenbark K; Lilienfeld D; Esterlitz J
    Ann Neurol; 1995 Nov; 38(5):771-7. PubMed ID: 7486869
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Parkinson's disease: managing symptoms and preserving function.
    Sweeney PJ
    Geriatrics; 1995 Sep; 50(9):24-31. PubMed ID: 7672615
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug management of Parkinson's disease.
    Kishore A; Snow BJ
    Can Fam Physician; 1996 May; 42():946-52. PubMed ID: 8688697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Parkinson's disease: drug therapy.
    Oertel WH; Quinn NP
    Baillieres Clin Neurol; 1997 Apr; 6(1):89-108. PubMed ID: 9426870
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.
    Shoulson I; Oakes D; Fahn S; Lang A; Langston JW; LeWitt P; Olanow CW; Penney JB; Tanner C; Kieburtz K; Rudolph A;
    Ann Neurol; 2002 May; 51(5):604-12. PubMed ID: 12112107
    [TBL] [Abstract][Full Text] [Related]  

  • 29. L-deprenyl in the treatment of Parkinson's disease.
    Csanda E; Tárczy M; Takáts A; Mogyorós I; Köves A; Katona G
    J Neural Transm Suppl; 1983; 19():283-90. PubMed ID: 6421993
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
    Larsen JP; Boas J
    Mov Disord; 1997 Mar; 12(2):175-82. PubMed ID: 9087975
    [TBL] [Abstract][Full Text] [Related]  

  • 31. R-(-)-deprenyl and parkinsonism.
    Yahr MD
    J Neural Transm Suppl; 1987; 25():5-12. PubMed ID: 3123605
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Parkinson's disease management strategies.
    Rajput A; Rajput AH
    Expert Rev Neurother; 2006 Jan; 6(1):91-9. PubMed ID: 16466316
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ["Widening horizons" in the clinical application of selegiline].
    Kovács A
    Acta Pharm Hung; 1992 Sep; 62(5):259-64. PubMed ID: 1488911
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An analysis of treatment options and outcome in patients with Parkinson's disease and severe dyskinesias.
    Mark MH; Sage JI
    Ann Clin Lab Sci; 1994; 24(1):12-21. PubMed ID: 8147565
    [TBL] [Abstract][Full Text] [Related]  

  • 35. R-(-)-deprenyl as a possible protective agent in Parkinson's disease.
    Tetrud JW; Langston JW
    J Neural Transm Suppl; 1987; 25():69-79. PubMed ID: 3123606
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacotherapy for Parkinson's disease.
    Chen JJ; Swope DM
    Pharmacotherapy; 2007 Dec; 27(12 Pt 2):161S-173S. PubMed ID: 18041936
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Amantadine for the treatment of levodopa dyskinesias in Parkinson's disease].
    Cersósimo MG; Scorticati MC; Micheli FE
    Medicina (B Aires); 2000; 60(3):321-5. PubMed ID: 11050808
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drugs for Parkinson's disease.
    Med Lett Drugs Ther; 1993 Apr; 35(894):31-4. PubMed ID: 8096322
    [No Abstract]   [Full Text] [Related]  

  • 39. Treatment strategies for extension of levodopa effect.
    LeWitt PA
    Neurol Clin; 1992 May; 10(2):511-26. PubMed ID: 1584187
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early combination therapy with bromocriptine and levodopa in Parkinson's disease.
    Factor SA; Weiner WJ
    Mov Disord; 1993 Jul; 8(3):257-62. PubMed ID: 8341289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.